

Special Issue

Post Tuberculosis Lung Disease from Lung Damage to the Loss of Lung Function

Message from the Guest Editors

The classification of post-tuberculosis (TB) chronic lung disorders continues to evolve, guidelines are missing, some disorders remain unclassifiable, and manifestations of treated pulmonary TB disease are ignored. It is a long journey from TB infection to active pulmonary TB disease, from contagious epidemiological status to lung damage and pulmonary impairment, with post-TB obstructive or restrictive disease and progressive loss of lung function. Appropriate approach and treatment must be developed, but only a comprehensive characterisation of pathogenesis, including etiological factors, biomarkers, phenotypes, and treatable traits, will allow for the introduction of precision preventive and curative medicine interventions. We invite colleagues to submit original research or review articles that contribute to the current body of knowledge on PTLD pathology, focussing in a broader sense on the pathogenic mechanisms that damage the lung and cause lung function loss. In this way, we hope to enhance the current understanding of the epidemiological, environmental, and immunological factors of disease development and progression and the therapeutic approach.

Guest Editors

Dr. Oana Cristina Arghir

Doctoral School of Medicine, Faculty of General Medicine, "Ovidius" University, 900470 Constanta, Romania

Dr. Ariadna Petronela Fildan

Faculty of Medicine, "Ovidius" University of Constanta, 900470 Constanta, Romania

Deadline for manuscript submissions

31 October 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/219741

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).